293 related articles for article (PubMed ID: 27349807)
21. Use of Terahertz-Raman Spectroscopy to Determine Solubility of the Crystalline Active Pharmaceutical Ingredient in Polymeric Matrices during Hot Melt Extrusion.
Bordos E; Islam MT; Florence AJ; Halbert GW; Robertson J
Mol Pharm; 2019 Oct; 16(10):4361-4371. PubMed ID: 31436094
[TBL] [Abstract][Full Text] [Related]
22. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
[TBL] [Abstract][Full Text] [Related]
23. The role of the polymer matrix in solvent-free hot melt extrusion continuous process for mechanochemical synthesis of pharmaceutical cocrystal.
Gajda M; Nartowski KP; Pluta J; Karolewicz B
Eur J Pharm Biopharm; 2018 Oct; 131():48-59. PubMed ID: 30205892
[TBL] [Abstract][Full Text] [Related]
24. Ball milling and hot-melt extrusion of indomethacin-l-arginine-vinylpyrrolidone-vinyl acetate copolymer: Solid-state properties and dissolution performance.
Iemtsev A; Zemánková A; Hassouna F; Mathers A; Klajmon M; Slámová M; Malinová L; Fulem M
Int J Pharm; 2022 Feb; 613():121424. PubMed ID: 34968683
[TBL] [Abstract][Full Text] [Related]
25. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
26. Probing the Molecular-Level Interactions in an Active Pharmaceutical Ingredient (API) - Polymer Dispersion and the Resulting Impact on Drug Product Formulation.
Yang F; Su Y; Small J; Huang C; Martin GE; Farrington AM; DiNunzio J; Brown CD
Pharm Res; 2020 May; 37(6):94. PubMed ID: 32405662
[TBL] [Abstract][Full Text] [Related]
27. Holistic QbD approach for hot-melt extrusion process design space evaluation: Linking materials science, experimentation and process modeling.
Evans RC; Bochmann ES; Kyeremateng SO; Gryczke A; Wagner KG
Eur J Pharm Biopharm; 2019 Aug; 141():149-160. PubMed ID: 31132400
[TBL] [Abstract][Full Text] [Related]
28. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution.
Chokshi RJ; Sandhu HK; Iyer RM; Shah NH; Malick AW; Zia H
J Pharm Sci; 2005 Nov; 94(11):2463-74. PubMed ID: 16200544
[TBL] [Abstract][Full Text] [Related]
29. Optimising Drug Solubilisation in Amorphous Polymer Dispersions: Rational Selection of Hot-melt Extrusion Processing Parameters.
Li S; Tian Y; Jones DS; Andrews GP
AAPS PharmSciTech; 2016 Feb; 17(1):200-13. PubMed ID: 26729536
[TBL] [Abstract][Full Text] [Related]
30. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol dispersing.
Dinunzio JC; Brough C; Hughey JR; Miller DA; Williams RO; McGinity JW
Eur J Pharm Biopharm; 2010 Feb; 74(2):340-51. PubMed ID: 19818402
[TBL] [Abstract][Full Text] [Related]
31. A Hot-Melt Extrusion Risk Assessment Classification System for Amorphous Solid Dispersion Formulation Development.
Kyeremateng SO; Voges K; Dohrn S; Sobich E; Lander U; Weber S; Gessner D; Evans RC; Degenhardt M
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631630
[TBL] [Abstract][Full Text] [Related]
32. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
[TBL] [Abstract][Full Text] [Related]
33. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion.
Forster A; Hempenstall J; Tucker ; Rades T
Drug Dev Ind Pharm; 2001 Jul; 27(6):549-60. PubMed ID: 11548862
[TBL] [Abstract][Full Text] [Related]
34. A fast and reliable empirical approach for estimating solubility of crystalline drugs in polymers for hot melt extrusion formulations.
Kyeremateng SO; Pudlas M; Woehrle GH
J Pharm Sci; 2014 Sep; 103(9):2847-2858. PubMed ID: 24634063
[TBL] [Abstract][Full Text] [Related]
35. From benchtop to pilot scale-experimental study and computational assessment of a hot-melt extrusion scale-up of a solid dispersion of dipyridamole and copovidone.
Zecevic DE; Evans RC; Paulsen K; Wagner KG
Int J Pharm; 2018 Feb; 537(1-2):132-139. PubMed ID: 29253586
[TBL] [Abstract][Full Text] [Related]
36. Selection of Solid-State Plasticizers as Processing Aids for Hot-Melt Extrusion.
Desai D; Sandhu H; Shah N; Malick W; Zia H; Phuapradit W; Vaka SRK
J Pharm Sci; 2018 Jan; 107(1):372-379. PubMed ID: 28923318
[TBL] [Abstract][Full Text] [Related]
37. A systematic and robust assessment of hot-melt extrusion-based amorphous solid dispersions: Theoretical prediction to practical implementation.
Alzahrani A; Nyavanandi D; Mandati P; Youssef AAA; Narala S; Bandari S; Repka M
Int J Pharm; 2022 Aug; 624():121951. PubMed ID: 35753536
[TBL] [Abstract][Full Text] [Related]
38. API solubility in semi-crystalline polymer: Kinetic and thermodynamic phase behavior of PVA-based solid dispersions.
Mathers A; Pechar M; Hassouna F; Fulem M
Int J Pharm; 2022 Jul; 623():121855. PubMed ID: 35623485
[TBL] [Abstract][Full Text] [Related]
39. Kollidon® VA 64 and Soluplus® as modern polymeric carriers for amorphous solid dispersions.
Strojewski D; Krupa A
Polim Med; 2022; 52(1):19-29. PubMed ID: 35766434
[TBL] [Abstract][Full Text] [Related]
40. Solvent-Assisted Hot Melt Extrusion of a Thermally Labile, High Melting Point Compound.
Lagan C; Huckle JE; Katz JM; Khorsand B; Daurio D; Andrews GP; Chung J; Alvarez-Nunez F
AAPS PharmSciTech; 2021 Sep; 22(7):235. PubMed ID: 34498147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
